These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 26669451)
1. UK BRCA mutation testing in patients with ovarian cancer. George A Br J Cancer; 2015 Dec; 113 Suppl 1(Suppl 1):S17-21. PubMed ID: 26669451 [TBL] [Abstract][Full Text] [Related]
2. Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature. Hoskins PJ; Gotlieb WH CA Cancer J Clin; 2017 Nov; 67(6):493-506. PubMed ID: 28881380 [TBL] [Abstract][Full Text] [Related]
3. The integration of BRCA testing into oncology clinics. Percival N; George A; Gyertson J; Hamill M; Fernandes A; Davies E; Rahman N; Banerjee S Br J Nurs; 2016 Jun; 25(12):690-4. PubMed ID: 27345073 [TBL] [Abstract][Full Text] [Related]
4. BRACAnalysis CDx as a companion diagnostic tool for Lynparza. Gunderson CC; Moore KN Expert Rev Mol Diagn; 2015; 15(9):1111-6. PubMed ID: 26292709 [TBL] [Abstract][Full Text] [Related]
5. Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer. Markman M Womens Health (Lond); 2018; 14():1745505717750694. PubMed ID: 29313444 [TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious Balasubramaniam S; Beaver JA; Horton S; Fernandes LL; Tang S; Horne HN; Liu J; Liu C; Schrieber SJ; Yu J; Song P; Pierce W; Robertson KJ; Palmby TR; Chiu HJ; Lee EY; Philip R; Schuck R; Charlab R; Banerjee A; Chen XH; Wang X; Goldberg KB; Sridhara R; Kim G; Pazdur R Clin Cancer Res; 2017 Dec; 23(23):7165-7170. PubMed ID: 28751443 [TBL] [Abstract][Full Text] [Related]
7. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy]. Schreiber V; Illuzzi G; Héberlé E; Dantzer F Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693 [TBL] [Abstract][Full Text] [Related]
8. Mainstreamed genetic testing for women with ovarian cancer: first-year experience. Rahman B; Lanceley A; Kristeleit RS; Ledermann JA; Lockley M; McCormack M; Mould T; Side L J Med Genet; 2019 Mar; 56(3):195-198. PubMed ID: 29535157 [TBL] [Abstract][Full Text] [Related]
9. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225 [TBL] [Abstract][Full Text] [Related]
10. Rucaparib: First Global Approval. Syed YY Drugs; 2017 Apr; 77(5):585-592. PubMed ID: 28247266 [TBL] [Abstract][Full Text] [Related]
11. PARP inhibitors in ovarian cancer: current status and future promise. Liu JF; Konstantinopoulos PA; Matulonis UA Gynecol Oncol; 2014 May; 133(2):362-9. PubMed ID: 24607283 [TBL] [Abstract][Full Text] [Related]
12. Hereditary ovarian cancer: biology, response to chemotherapy and prognosis. Safra T Womens Health (Lond); 2009 Sep; 5(5):543-53. PubMed ID: 19702453 [TBL] [Abstract][Full Text] [Related]
14. Leveraging DNA repair deficiency in gynecologic oncology. Walsh CS; Hodeib M Curr Opin Obstet Gynecol; 2016 Feb; 28(1):24-31. PubMed ID: 26694829 [TBL] [Abstract][Full Text] [Related]
15. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer. Gunderson CC; Moore KN Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679 [TBL] [Abstract][Full Text] [Related]
16. Olaparib recommendations for ovarian cancer patients. Johnson P; Westcott G Future Oncol; 2016 Jan; 12(2):149-51. PubMed ID: 26616222 [TBL] [Abstract][Full Text] [Related]
17. Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies. Long KC; Kauff ND Curr Opin Oncol; 2011 Sep; 23(5):526-30. PubMed ID: 21734577 [TBL] [Abstract][Full Text] [Related]
18. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Moyer VA; Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376 [TBL] [Abstract][Full Text] [Related]
19. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443 [TBL] [Abstract][Full Text] [Related]
20. Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal. Tinelli A; Malvasi A; Leo G; Vergara D; Pisanò M; Ciccarese M; Chiuri VE; Lorusso V Cancer Metastasis Rev; 2010 Jun; 29(2):339-50. PubMed ID: 20405170 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]